EXSCIENTIA
21.7.2021 10:02:06 CEST | Business Wire | Press release
Exscientia , an AI-driven pharmatech company with a mission to revolutionise how drugs are discovered, and GT Apeiron Therapeutics （Apeiron） , a Shanghai based company focused on novel oncology drugs, announced today a strategic research and development collaboration agreement. The collaboration will leverage the patient-centric AI-first capabilities of Exscientia to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies. All pipeline products will be equally owned and Exscientia holds an equity stake in Apeiron.
This expanded collaboration follows the successful design of multiple selective CDK7 compounds. The potent, highly selective, non-covalent CDK7 compounds have demonstrated consistent tumour responses in xenograft models as well as exceptional pharmacokinetics. In addition, using live primary tissue samples from ovarian cancer patients, the CDK7 inhibitors showed both enhanced tumour cell cytotoxicity as well as selectivity over immune cells in the same microenvironment.
“Based on what they have already achieved , Exscientia is clearly the leader in AI-driven drug discovery, and we have witnessed this first-hand in our collaboration so far,” stated Dr. Mingxi Li, President of GT Apeiron Therapeutics. “We have been incredibly impressed by the combined power of the AI design and use of patient data to optimize and select molecules that are more likely to give positive effects in the clinic. This joint venture is a significant step in building GT Apeiron’s valuable and robust pipeline of CDK inhibitor drugs and substantially accelerates our early-stage output and progression towards being a clinical stage biotech company.”
“We are driven to bring drugs to market that make a difference for patients,” says Andrew Hopkins, chief executive officer of Exscientia. “Apeiron bring a focus and an expertise on the biological basis of multiple cancers and helps us to create better drugs for better outcomes in the clinic and beyond. This collaboration has already proven to be capable of delivering potential drug candidates with promising patient-relevant data, and we look forward to extending that into a portfolio of multiple clinical assets.”
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai Social media: Twitter @exscientiaAI . LinkedIn https://www.linkedin.com/company/ex-scientia/
About GT Apeiron Therapeutics
GT Apeiron Therapeutics is strategically based in Shanghai and in the San Francisco Bay Area, with significant collaborations in the UK enabling us to tap into technologies and talent from all three continents. Our team and partners bring together deep expertise in oncology and drug discovery to enable efficient and scalable discovery and development of novel drugs. To learn more, visit http://www.apeiron-bio.com/ Social media: LinkedIn https://www.linkedin.com/company/gt-apeiron-therapeutics/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005394/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Royal Moroccan Football Federation Acknowledges Decision Rendered by the CAF Appeals Committee18.3.2026 18:49:00 CET | Press release
The Royal Moroccan Football Federation (FRMF) wishes to reiterate that its appeal was never aimed at contesting the sporting merit or performance of the teams involved in this tournament, but solely to ensure the proper enforcement of competition regulations. The federation reaffirms its commitment to respecting the regulations, ensuring the clarity of the competitive framework and maintaining the stability of African football competitions. The Federation also wishes to commend all the nations that participated in this year’s edition of the Africa Cup of Nations (AFCON), which served as a significant moment for African football. The FRMF will issue a more comprehensive official statement in the coming days after a scheduled meeting of its governing bodies. Source: AETOSWire View source version on businesswire.com: https://www.businesswire.com/news/home/20260318763307/en/
SIMCON Unveils World’s First Large Engineering Model for Plastic Injection Moulding18.3.2026 18:05:00 CET | Press release
SIMCON today announced the launch of the Cadmould AI Solver, the world’s first Large Engineering Model for injection moulding. Co-developed with Emmi AI, the new transformer-based architecture delivers simulation results up to 1000 times faster than traditional numerical solvers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318680159/en/ SIMCON’s new Cadmould AI Solver delivers injection molding simulation results in seconds. By removing lengthy computation times, the tool enables engineers to dynamically explore thousands of design and process variations in a single day. Historically, lengthy computation times have acted as a bottleneck, limiting the number of design variations engineers can practically explore during the development process. The Cadmould AI Solver shatters this barrier by providing engineers with instant feedback on filling pattern, pressure, and temperature in seconds. What once required hours per si
Boomi, a 12X Leader, Positioned Highest for Ability to Execute in the 2026 Gartner® Magic Quadrant™ for Integration Platform as a Service18.3.2026 16:30:00 CET | Press release
Boomi™, the data activation company, today announced it has been recognized as a Leader and positioned highest for Ability to Execute in the 2026 Gartner® Magic Quadrant™ for Integration Platform as a Service (iPaaS). This marks the 12th consecutive time Boomi has been named a Leader– the longest recognized vendor in the report’s history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318987091/en/ Boomi, a 12X Leader, Positioned Highest for Ability to Execute in the 2026 Gartner® Magic Quadrant™ for Integration Platform as a Service Boomi attributes its continued industry recognition to its unwavering commitment to innovation, customer success, and ecosystem growth. Over the past year, Boomi has accelerated its investments in integration and automation, APIM, agent management, and data management to help enterprises transform fragmented systems and data into orchestrated processes and governed agentic workflows. Recent i
Laserfiche Announces 2026 Run Smarter® Award Winners18.3.2026 15:17:00 CET | Press release
Laserfiche — the leading SaaS provider of intelligent content management — today announced the winners of the 2026 Laserfiche Run Smarter® Awards. These awards celebrate the visionaries and trailblazers who are redefining the possible, using Laserfiche to break down operational silos and catalyze a new era of enterprise-wide productivity. From a large city reimagining criminal justice to a financial services firm’s innovative use of AI for smarter service delivery: The winners enhance productivity, reimagine processes and improve lives with Laserfiche technology. “The true power of Laserfiche has always been in how it unlocks value — whether that is through delivering actionable intelligence, cost savings, or reclaimed time to put toward innovation,” said Karl Chan, CEO of Laserfiche. “This year’s honorees are at the forefront of information management, with many of them leveraging cloud and AI technology to modernize processes and achieve business transformation.” Congratulations to t
I-Pulse Acquires CSI Technologies to Strengthen U.S. High-Energy Capacitor Manufacturing Capabilities18.3.2026 14:30:00 CET | Press release
I-Pulse Acquires California Capacitor Specialist CSI Technologies to Advance Disruptive Pulsed Power ApplicationsCSI Acquisition Secures Strategic Technologies Central to I-Pulse’s Pulsed Power Roadmap Co-Founder, Chairman, and CEO, Robert Friedland, and Co-Founder and Chief Technology Officer, Laurent Frescaline, of I-Pulse, the world leader in high pulsed power technologies, are pleased to announce the acquisition of CSI Technologies, Inc., the California-based manufacturer of high-energy, high-voltage capacitors serving industrial, medical, and defense applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318099794/en/ The strategic acquisition enhances I-Pulse’s pulsed power development and U.S. manufacturing capabilities, particularly in mining, geothermal energy, mineral exploration, and water resource applications. By integrating CSI Technologies’ proven capacitor design and production expertise, I-Pulse str
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom